About Innocoll

Innocoll is a biotherapeutics pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

Latest News

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and...
Read More

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant

Results of implant’s safety, efficacy and pharmacokinetics for use in various open soft-tissue surgeries expected in first quarter 2022 April...
Read More

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

ATHLONE, Ireland – Feb. 4, 2021 – Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point...
Read More